Preventive Effects of Cetylpyridinium Chloride on SarcopeniaStudy

• Status: Completed
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to assess the impact on the prevention of sarcopenia after taking cetylpyridinium chloride targeting the patients of presarcopenia over the age of 60.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Cetylpyridinium

Criteria

Inclusion Criteria:

• Presarcopenia A. Reduced skeletal muscle mass (ASM/height2) M < 7.0kg/m2, F < 5.7kg/m2 B. Normal grip strength M ≥ 26kg, F ≥ 18kg C. Normal physical performance Gait speed > 0.8m/s

• Community dwelling

Exclusion Criteria:

• History of stroke or spinal cord injury

• Artificial joint

• Acute disease or unstable chronic disease

• Phenylketonuria

• History of myocardiac infarction

• Allergic contact dermatitis

• History of drug/alcohol addiction, habitual smoker